

ODMA\MI\ODMA\MANAGE\238747;1
 DEB/BWM/cmm
 07/06/01

PATENT APPLICATION
 DOCKET NO.: 3028.1000-000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Guy A. Rouleau and Bernard Brais


Application No.: 09/590,211

Group Art Unit: 1632

Filed: June 8, 2000

Examiner:

Title: SHORT GCG EXPANSIONS IN THE PAB II GENE FOR
 OCULOPHARYNGEAL MUSCULAR DYSTROPHY AND DIAGNOSTIC
 THEREOF



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
 Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
 (First/Second submission after final rejection)
- ☒ under 37 CFR 1.97(b), or
 (Within any one of the following time periods: three months of filing national application (other than a CIPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CIPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(c), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
 (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(c), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
 (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
 Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

69/590,211

-2-

Statement Under 37 CFR 1.97(c)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

☒ Enclosed herewith is form PTO-1449:

☒ Copies of the cited references are enclosed.

☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]

☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:

☐ the explanation provided on the attached sheet.

☐ the explanation provided in the Specification.

☐ submission of the enclosed International Search Report.

☐ the enclosed English language abstract.

☐ Applicant requests that the following pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

Examiner_____
Date

09/590,211

-3-

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

David E. Brock RN 22592

By *Elizabeth W. Mata*

Elizabeth W. Mata

Registration No.: 38,236

Telephone: (781) 861-6240

Facsimile: (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: *7/9/01*

DOC ID NO. 3028.1000-000

PTO-1449 PREVIOUS

ATTORNEY DOCKET NO.
3028.1000-000APPLICATION NO.
09/590,211INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

July 6, 2001

(Use several sheets if necessary)

APPLICANT
Guy A. Rouleau, et al.FILING DATE
June 8, 2000GROUP
1632

U.S. PATENT DOCUMENTS

EXAM- INER INITI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AX3	Tonè M.S., et al., "Nuclear Inclusions in Oculopharyngeal Dystrophy", Acta Neuropathologica, 49:85-87 (1980).
AY3	Lafrènière R.G., et al., "Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1", Nature Genetics, 15:298-302 (March 1997).
AZ3	Ronancus J.M., et al., "Towards a Transcriptional Map of the q21-q22 Region of Chromosome 7", Plenum Press, pp:65-79 (1994).

EXAMINER

DATE CONSIDERED